Hanmi pharmaceutical Co., Ltd.
Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years.
Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies.
Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories.
As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.
Beijing Hanmi Pharmaceutical Co.,Ltd
Hanmi Pharmaceuticals established its subsidiary Beijing Hanmi in 1996 and it has been recognized as the most successful case of glocalization among Korean pharmaceutical companies for entering Chinese market. Beijing Hanmi, equipped with Research & Development Center, GMP plant and nation-wide sales forces in China, has been demonstrating dramatic top-line growth, posting over 20% CAGR for the recent years.
The company markets over 20 products in a variety of treatment areas at present. Major products currently generating sizeable sales include Mami Ai (pediatric digestive supplement with lactic acid bacteria), Etanjing (cough medicine), and Mechanang (gastrointestinal treatment). In addition, Beijing Hanmi Research Center is working on a number of collaborative R &D projects with Hanmi Research Center in Korea in order to accelerate the launch of new products in the global market.
Hanmi Medicare Co.,Ltd
Hanmi Medicare Co., Ltd is manufacturing and marketing various range of healthcare products including medical devices, healthcare foods and beverages. Guardix (anti-adhesive agent) has become the main product of our medical devices department generating annual sales of 20 million dollars. HAL&RAR treatment which enables patients to be discharged on the day of operation with minimal post operative pain is now also widely used in specialty hospitals.
Healthcare food business department supplies various healthcare foods produced using advanced R&D technology under strict quality control. Soybean milk made from patented technology of grinding soybean as a whole, ensuring all nutrients and taste remain in their natural state is beloved by many customers.
Established in 2005 and has been focused on the development of enterprise solution, consulting, and total outsourcing of enterprise network. Based on know-how acquired through having built a computerized environment for a variety of companies, Hanmi IT is proceeding toward system integration such as operating portal sites for pharmacists, doctors and hospitals, mobile phone business in China, RFID, and the development of mobile middleware.
Hanmi Japan Pharmaceutical Co.,Ltd
Hanmi Japan Pharmaceutical Co. Ltd was established in 2007 as part of Hanmi's strategic expansion into Japan's pharmaceutical market.
Using Hanmi's platform technology we are constantly reviewing opportunities in developing new anticancer, bio-better, and combination drugs for the Japanese market. To facilitate cross-licensing of key technologies Hanmi is expanding its partnerships with esteemed Japanese pharmaceutical entities.